Last reviewed · How we verify
NCT05164523
The Effect of SGLT2 Inhibitors on Heart Rate Variability and BDNF Levels in Patients With Type 2 Diabetes
trial testing 24-hour rhythm Holter in Type 2 Diabetes in 64 participants. Completed in 30 December 2022.
21 December 2022
Quick facts
| Lead sponsor | Goztepe Training and Research Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 64 |
| Start date | 1 March 2021 |
| Primary completion | 21 December 2022 |
| Estimated completion | 30 December 2022 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- 24-hour rhythm Holter
- 36 item Short Form Survey (SF-36)
Conditions studied
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
- Heart Rate Variability — all drugs for Heart Rate Variability →
Sponsor
Goztepe Training and Research Hospital
Who can join
Adults 30 to 80, any sex, with Type 2 Diabetes or Heart Rate Variability. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cardiac autonomic neuropathy (CAN) in diabetic patients is an indicator of autonomic nervous system dysfunction and is an important marker for cardiovascular events. Very promising results have been obtained with SGLT2 inhibitors in both cardiac and renal outcomes. The aim is to examine the effects of SGLT2 inhibitor use on cardiac autonomic neuropathy, heart rate variability, sympathetic and parasympathetic nervous system parameters, and their relationship with BDNF levels, one of the neuroinflammatory markers.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05164523
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 2 Diabetes
Currently open trials in the same condition.
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07254689 — The Food for Health Study · NA · recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Other Goztepe Training and Research Hospital trials
Trials by the same sponsor.
- NCT07302061 — "Effects of Fluid Status and Regional Cerebral Oxygenation on Postoperative Cognitive Dysfunction in Patients Undergoing · active not recruiting
- NCT05394571 — Conditions Associated With Poorly Controlled Diabetes in Patients With Type 2 Diabetes and HbA1c Changes With Therapy · completed
- NCT05188391 — A New Method for Deltoid Ruptures: Gap Sign · NA · unknown
- NCT05062616 — Patient Satisfaction After Ingrown Toenail Surgery · completed
- NCT05341388 — The Effect of SGLT2 Inhibitors on Cognitive Functions and BDNF Levels in Patients With Type 2 Diabetes · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05164523 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Goztepe Training and Research Hospital
- Last refreshed: 5 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05164523.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing